Share this video  

GU Cancers 2018 | SPARTAN vs. PROSPER: apalutamide or enzalutamide for nmCRPC?

With exciting data from the Phase III SPARTAN (NCT01946204) and PROSPER (NCT02003924) trials of apalutamide and enzalutamide, respectively, for the treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC), a question arising is which drug is better. Speaking from the 2018 Genitourinary Cancers Symposium, in San Francisco, CA, Eric Small, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses this question.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter